The metabolic syndrome

Pathologie Biologie

Volumn 54, Issue 7, 2006, Pages 375-386

  Fulop, T ^a   Tessier, D ^a   Carpentier, A ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Adipose tissue; Aging innate immunity; Cytokines; Inflammation; Insulin resistance; Obesity

Indexed keywords

ACETYLSALICYLIC ACID; ADIPOCYTOKINE; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN RECEPTOR; LIPID; METFORMIN;

ADIPOSE TISSUE; AGING; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; DIET THERAPY; DISEASE COURSE; EPIDEMIC; HUMAN; INCIDENCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KINESIOTHERAPY; LIFESTYLE; LIPID METABOLISM; MACROPHAGE; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; QUALITY OF LIFE; RISK FACTOR; SIGNAL TRANSDUCTION; VASCULARIZATION;

BLOOD CIRCULATION; BLOOD PRESSURE; HUMANS; INFLAMMATION; INSULIN; LIPIDS; METABOLIC SYNDROME X; OBESITY;

EID: 33749129189     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2006.07.002     Document Type: Article

References (124)

1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
2. Kylin E. Studien ueber das Hypetonie-Hyperglykemia-Hyperurikemiasyndrom. Zentralblatt fuer Inere Medizin. 44 (1923) 105-127
3. Magliano D.J., Shaw J.E., and Zimmet P.Z. How to best define the metabolic syndrome. Ann. Med. 38 (2006) 34-41
4. Zimmet P., Alberti K.G.M.M., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
5. World Health Organization. Definition, diagnosis and classification diabetes mellitus and its complications (1999) (Report of a WHO consultation)
6. Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults. executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
7. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels, Belgium: International Diabetes Federation; 2004. Available at: http://www.idf.org/webdata/docs/metabolic_syndrome_definifiton.pdf. Accessed June 15, 2005.
8. Alberti K.G.M.M., Zimmet P., Shaw J., and for the IDF Epidemiology Task Force Consensus Group. Lancet 366 (2005) 1059-1062
9. Carr D.B., Utzschneider K.M., Hull R.L., Kodama K., Retzlaff B.M., Brunzell J.D., et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53 (2004) 2087-2094
10. Egan B.M., Papademetriou V., Wofford M., Calhoun D., Fernandes J., Riehle J.E., et al., TROPHY Sub-study Investigative Team. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am. J. Hypertens. 18 (2005) 3-12
11. Resnick H.E., Jones K., Ruotolo G., Jain A.K., Henderson J., Lu W., et al., Strong Heart Study. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26 (2003) 861-867
12. American College of Endocrinology Task Force on the insulin resistance syndrome. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9 (2003) 236-252
13. Liao Y., Kwon S., Shaughnessy S., Wallace P., Hutto A., Jenkins A.J., et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27 (2004) 978-983
14. Lemieux I., Pascot A., Couillard C., Lamarche B., Tchernof A., Almeras N., et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation 102 (2000) 179-184
15. Grundy S.M. Point: the metabolic syndrome still lives. Clin. Chem. 51 (2005) 1352-1354
16. Bonora E. The metabolic syndrome and cardiovascular disease. Ann. Med. 38 (2006) 64-80
17. Laakso M., and Kovanen P.T. Metabolic syndrome: to be or not to be?. Ann. Med. 38 (2006) 32-33
18. Bonadonna R.C., Del Prato S., Saccomani M.P., Bonora E., Gulli G., Ferrannini E., et al. Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. J. Clin. Invest. 92 (1993) 486-494
19. Gastaldelli A., Baldi S., Pettiti M., Toschi E., Camastra S., Natali A., et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49 (2000) 1367-1373
20. Virtanen K.A., Iozzo P., Hallsten K., Huupponen R., Parkkola R., Janatuinen T., et al. Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes: a positron-emitting tomography study. Diabetes 54 (2005) 2720-2726
21. Del Prato S., Leonetti F., Simonson D.C., Sheehan P., Matsuda M., and DeFronzo R.A. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 37 (1994) 1025-1035
22. Kissebah A.H., and Peiris A.N. Biology of regional body fat distribution: relationship to non-insulin-dependent diabetes mellitus. Biabetes Metab Rev. 5 (1989) 83-109
23. Golay A., Swislocki A.L., Chen Y.D., and Reaven G.M. Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism 36 (1987) 692-696
24. Ferrannini E., Barrett E.J., Bevilacqua S., and DeFronzo R.A. Effect of fatty acids on glucose production and utilization in man. J. Clin. Invest. 72 (1983) 1737-1747
25. Groop L.C., Saloranta C., Shank M., Bonadonna R.C., Ferrannini E., and DeFronzo R.A. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 72 (1991) 96-107
26. Taskinen M.R. Type 2 diabetes as a lipid disorder. Curr. Mol. Med. 5 (2005) 297-308
27. Ginsberg H.N. New perspective on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 106 (2002) 2137-2142
28. Steinberg H.O., and Baron A.D. Vascular function, insulin resistance and fatty acids. Diabeteologia 45 (2002) 623-634
29. Ferrannini E., Natali A., Capaldo B., Lehtovirta M., Jacob S., and Yki-Jarvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 30 (1997) 1144-1149
30. Montagnani M., Ravichandran L.V., Chen H., Esposito D.L., and Quon M.J. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol. Endocrinol. 16 (2002) 1931-1942
31. Ferrannini E. Is insulin resistance the cause of the metabolic syndrome?. Ann. Med. 38 (2006) 41-42
32. Gastaldelli A., Sironi A.M., Ciociaro D., Positano V., Buzzigoli E., Giannessi D., et al. Visceral fat and beta cell function in non-diabetic humans. Diabetologia 48 (2005) 2090-2096
33. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J. Clin. Invest. 106 (2000) 473-481
34. Gimeno R.E., and Klaman L.D. Adipose tissue as an active endocrine organ: recent advances. Curr. Opin. Pharmacol. 5 (2005) 122-128
35. Hutley L., and Prins J.B. Fat as an endocrine organ: relationship to the metabolic syndrome. Am. J. Med. Sci. 330 (2005) 280-289
36. Després J.P. Is visceral obesity the cause of the metabolic syndrome?. Ann. Med. 38 (2006) 52-63
37. Despres J.P., Nadeau A., Tremblay A., Ferland M., Moorjani S., Lupien P.J., et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 38 (1989) 304-309
38. Bacha F., Saad R., Gungor N., Janosky J., and Arslanian S.A. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J. Clin. Endocrinol. Metab. 88 (2003) 2534-2540
39. Giles T.D., and Sander G.E. Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome. J. Clin. Hypertens. 7 (2005) 669-678
40. Arner P. Free fatty acids do they play a central role in type 2 diabetes?. Diabetes Obes. Metab. Supl 1 (2001) S11-S19
41. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., and Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95 (1995) 2409-2415
42. Porter M.H., Cutchins A., Fine J.B., Bai Y., and DiGirolamo M. Effects of TNF-alpha on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations. J. Lab. Clin. Med. 139 (2002) 140-146
43. Sonnenberg G.E., Krakower G.R., and Kissebah A.H. A novel pathway to the manifestations of metabolic syndrome. Obes. Res. 12 (2004) 180-186
44. Matsuda M., Shimomura I., Sata M., Arita Y., Nishida M., Maeda N., et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J. Biol. Chem. 277 (2002) 37487-37491
45. Stefan N., and Stumvoll M. Adiponectin-its role in metabolism and beyond. Horm. Metab. Res. 34 (2002) 469-474
46. Berg A.H., Combs T.P., and Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 13 (2002) 84-89
47. Gil-Campos M., Canete R.R., and Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin. Nutr. 23 (2004) 963-974
48. Iwashima Y., Katsuya T., Ishikawa K., Ouchi N., Ohishi M., Sugimoto K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43 6 (2004) 1318-1323
49. Shimabukuro M., Higa N., Asahi T., Oshiro Y., Takasu N., Tagawa T., et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J. Clin. Endocrinol. Metab. 88 (2003) 3236-3240
50. Lyon C.J., Law R.E., and Hsueh W.A. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144 (2003) 2195-2200
51. White D.W., and Tartaglia L.A. Leptin and OB-R: body weight regulation by a cytokine receptor. Cytokine Growth Factor Rev. 7 (1996) 303-309
52. Kralisch S., Klein J., Lossner U., Bluher M., Paschke R., Stumvoll M., et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J. Endocrinol. 185 (2005) R1-R8
53. Plutzky J. Inflammation in atherosclerosis and diabetes mellitus. Rev Endocrinol. Metab. Disord. 5 (2004) 255-259
54. Santos A.C., Lopes C., Guimarâes J.T., and Barros H. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int. J. Obes. 29 (2005) 1452-1456
55. Ridker P., Buring J., Cook N., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107 (2003) 391-397
56. Yudkin J.S., Stehouwer C.D., Emeis J.J., and Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 972-978
57. Hak A.E., Stehouwer C.D., Bots M.L., Polderman K.H., Schalkwijk C.G., Westendorp I.C., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1986-1991
58. Festa A., D'Agostino Jr. R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
59. Pickup J.C., Mattock M.B., Chusney G.D., and Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40 (1997) 1286-1292
60. Pickup J.C. Inflammatory markers and type 2 diabetes. Diabetes Tech. Therap. 8 (2006) 1-6
61. Ozcan U., Cao Q., Tilmaz E., Lee A.H., Iwakoshi N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306 (2004) 457-461
62. Klein-Platat C., Drai J., Oujaa M., Schlienger J.L., and Simon C. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am. J. Clin. Nutr. 82 (2005) 1178-1184
63. Kolb H., and Mandrup-Poulsen T. An immune origin of type 2 diabetes?. Diabetologia 48 (2005) 1038-1050
64. Weisberg S.P., McCan D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (2003) 1796-1808
65. Xu H., Barnes G.T., and Yang Q. Chronic inflammation in fat plays a critical role in the development of obesity related insulin resistance. J Clin Invest 112 (2003) 1821-1830
66. Murdolo G., and Smith U. The dysregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis. Nutr. Metab. Cardiovasc. Dis. 16 (2006) 535-538
67. Charrière G., Cousin B., Arnaud E., André M., Bakou F., and Penicaud L. Preadipocyte conversion to macrophage. Evidence of plasticity. J. Biol. Chem. 11 (2003) 9850-9855
68. Makowski L., Boord J.B., Maeda K., Babaev V.R., Uysal K.T., Morgan M.A., et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7 (2001) 699-705
69. Wellen K.E., and Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 115 (2005) 1111-1119
70. Koh K.K., Hwan Han S., and Quon M.J. Inflammatory markers and the metabolic syndrome. J. Am. Coll. Cardiol. 46 (2005) 1978-1985
71. Ito H., Ohshima A., Inoue M., Ohto N., Nakasuga K., Kaji Y., et al. Weight reduction decreases soluble cellular adhesion molecules in obese women. Clin. Exp. Pharmacol. Physiol. 29 5-6 (2002) 399-404
72. Troseid M., Lappegard K.T., Claudi T., Damas J.K., Morkrid L., Brendberg R., et al. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur. Heart J. 25 (2004) 349-355
73. Endres S., Ghorbani R., Kelley V.E., Georgilis K., Lonnemann G., van der Meer J.W., et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N. Engl. J. Med. 320 (1989) 265-271
74. Browning L., and Jebb S.A. Nutritional influences on inflammation and type 2 diabetes risk. Diabetes Technol. Ther. 8 (2006) 45-54
75. Lee J.Y., and Hwang D.H. The modulation of inflammatory gene expression by lipids: mediation through toll-like receptors. Mol. Cells 21 (2006) 174-185
76. Shepherd P.R. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol. Scand. 183 (2005) 3-12
77. White M.F. Yhe insulin signalling system and the IRS proteins. Diabetologia 40 Suppl 2 (1997) S2-S17
78. Schinner S., Scherbaum W.A., Bornstein S.R., and Barthel A. Molecular mechanisms of insulin resistance. Diabet. Med. 22 (2004) 674-682
79. Plomgaard P., Bouzakri K., Krogh-Madsen R., Mittendorfer B., Zierath J.R., and Pedersen B.K. Tumor necrosis factor-x induces skeletal muscle insulin resistance in healthy human subjects via inhibition of akt substrate 160 phosphorylation. Diabetes 54 (2005) 2939-2945
80. Ruan H., and Lodish H.F. Regulation of insulin sensitivity by adipose tissue-derived hormones and inflammatory cytokines. Curr. Opin. Lipidol. 15 (2004) 297-302
81. Ruan H., and Lodish H.F. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev. 14 (2003) 447-455
82. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 115 (2005) 911-919
83. Kovacs P., and Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best practice and research. Clinical Endocrinology & Metabolism 19 (2005) 625-635
84. 12 cells. Diabetologia 48 (2005) 1386-1392
85. Björnholm M., and Zierath J.R. Insulin signal transduction in human skeletal muscle: identifying the defects in type II diabetes. Biochem. Soc. Trans. 33 (2005) 354-361
86. Ueno M., Carvalheira J.B.C., Tambascia R.C., Bezerra R.M.N., Amaral M.E., Carneiro E.M., et al. Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia 48 (2005) 506-518
87. Zick Y. Uncoupling insulin signalling by serin/threonine phosphorylation: a molecular basis for insulin resistance. Biochem. Soc. Trans. 32 (2004) 812-816
88. Ogihara T., Asano T., Katagiri H., Sakoda H., Anai M., Shojima N., et al. Oxidative stress induces insulin resistance by activating the nuclear factor-kB pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase. Diabetologia 47 (2004) 794-805
89. Nakatani Y., Kaneto H., Kawamori D., Yoshiuchi K., Hatazaki M., Matsuoka T.A., et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J. Biol. Chem. 280 (2005) 847-851
90. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114 (2004) 1752-1761
91. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
92. Duncan B.B., and Schmidt M.I. The epidemiology of low-grade chronic systemic inflammation and type 2 diabetes. Diabetes Technolog & Therapeutics 8 (2006) 7-17
93. Vettor R., Milan G., Rossato M., and Federspil G. Review article: adipocytokines and insulin resistance. Aliment. Pharmacol. Ther. 22 Suppl. 2 (2005) 3-10
94. Haffner S. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol. Suppl 3 (2006) 3A-11A
95. Perseghin G., Petersen K., and Shulman G.I. Cellular mechanism of insulin resistance: potential links with inflammation. Int. J. Obes. Relat. Metab. Disord. 27 Suppl 3 (2003) S6-S11
96. Senn J.J., Klover P.J., Nowak I.A., Zimmers T.A., Koniaris L.G., Furlanetto R.W., et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 278 16 (2003) 13740-13746
97. Third National Health and Nutrition Examination Survey (NCEP). NCEP-defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
98. Third report of the of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
99. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
100. Bechtold M., Palmer J., Valtos J., Iasiello C., and Sowers J. Metabolic syndrome in the elderly. Curr. Diab. Rep. 6 (2006) 64-71
101. Morley J.E. The metabolic syndrome and aging. J. Gerontol. 59A (2004) 139-142
102. Boehm B.O., and Claudi-Boehm S. The metabolic syndrome. Scand. J. Clin. Lab. Invest. 65 Suppl 240 (2005) 3-13
103. Janssen I., and Ross R. Linking age-related changes in skeletal muscle mass and composition with metabolism and disease. J. health Nutr. Aging 9 6 (2005) 408-419
104. Goodpaster B.H. Measuring body fat distribution and content in humans. Curr. Opin. Clin. Nutr. Metab. Care 5 5 (2002) 481-487
105. Franceschi C., Olivieri F., Marchegiani F., Cardelli M., Cavallone L., Capri M., et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech. Ageing Dev. 126 2 (2005) 351-361
106. Pawelec G., Akbar A., Caruso C., Solana R., Grubeck-Loebenstein B., and Wikby A. Human immunosenescence: is it infectious?. Immunol. Rev. 205 (2005) 257-268
107. Yang J., Anzo M., and Cohen P. Control of aging and longevity by IGF-I signaling. Exp Geront. 40 (2005) 867-872
108. Hughes K.A., and Reynolds R.M. Evolutionary and mechanistic theories of aging. Annu. Rev. Entomol. 50 (2005) 421-445
109. Bartke A. Long lived Klotho mice: new insights into the roles of IGF-1 and insulin in aging. Trends Endocrinol. Metab. 17 (2006) 33-35
110. Laron Z. Do deficiencies in growth hormone and insulin like growth factor-1 (IGF-1) shorten or prolong longevity?. Mech. Ageing Dev. 126 (2005) 305-307
111. Rincon M., Rudin E., and Barzilai N. The insulin/IGF-1 signalling in mammals and its relevance to human longevity. Exp Geront. 40 (2005) 873-877
112. Barzilai N., Atzmon G., Schechter C., Schaefer E.J., Cupples A.L., Lipton R., et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290 15 (2003) 2030-2040
113. Zambon A., Pauletto P., and Crepaldi G. Review article: the metabolic syndrome a chronic cardiovascular inflammatory condition. Aliment. Pharmacol. Ther. 22 Suppl. 2 (2005) 20-23
114. Lau D.C.W., Yan H., and Dhillon B. Metabolic syndrome: a marker of patients at high cardiovascular risk. Can. J. Cardiol. 22 (2006) 85B-90B
115. Hashizume K., Suzuki S., Hara M., Komatsu A., and Yamashita K. Metabolic syndrome and age-related dementia: endocrinological aspects of adaptation to aging. Mech. Ageing Dev. 127 (2006) 507-510
116. Craft S. Insulin resistance syndrome and Alzheimer disease: age and obesity-related effects on memory, amyloid and inflammation. Neurobiol. Aging 26 (2005) S65-S69
117. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al., Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344 (2001) 1343-1350
118. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al., Diebetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
119. Colca J.R. Insulin sensitizers may prevent metabolic inflammation. Biochem. Pharmacol. 72 (2006) 125-131
120. Athyros V.G., Elisaf M., and Mikhalidis D.P. Inflammatory markers and the metabolic syndrome. Atherosclerosis 183 (2005) 187-188
121. Schernthaner G.H., and Schernthaner G. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention. Scand. J. Clin. Lab. Invest. 65 Suppl 240 (2005) 30-40
122. Shaw S.G., and Boden J.P. Insulin resistance, obesity and the metabolic syndrome. Is a there a therapeutic role for endothelin-1 antagonists?. Current Vascular Pharmacology 3 (2005) 359-363
123. Wyne K.L. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy. Diabetes Obes. Metab. 8 4 (2006) 365-380
124. Bernardi R., Cosentino E.R., and Borghi C. Metabolic syndrome and hypertension: prevention and treatment. Minerva Med. 97 2 (2006) 123-141